They found that targeting these necroptotic proteins through genetic and pharmacological interventions using RIPK1/RIPK3/MLKL shRNA, Nec-1, and NSA ameliorated MN degeneration and improved motor performance, supporting the role of necroptosis in ALS pathogenesis. This evidence concerns the gene MLKL and amyotrophic lateral sclerosis.